氟达拉滨联合米托蒽醌、地塞米松治疗惰性淋巴瘤疗效分析  

Analysis on efficacy of fludarabin combined with mitoxantrone or dexamethasone in treatment of indolent lymphoma

作　　者：刘晰宇[1] 何执鼎[1] 易平勇[1] 周芳[1] 孙中义[1] 黄利军[1] 贺军侨[1] 

机构地区：[1]湖南省肿瘤医院内五科,湖南长沙410013

出　　处：《世界肿瘤杂志》2008年第1期28-30,共3页Tumour Journal of the World

摘　　要：目的比较氟达拉滨（FLU）联合米托蒽醌（MIT）、地塞米松（DXM）（FMD方案）与CHOP方案治疗惰性淋巴瘤的疗效。方法73例初、复治惰性淋巴瘤病人分3组。A组：FMD初治组；B组：FMD复治组；C组：CHOP方案治疗组。结果A组的CR率为59．1％，高于B组的CR率28．6％（P〈0．05），A组的总有效率（CR＋PR）86.4％，高于B组的总有效率（CR＋PR）57．1％（P〈0．05）。A组的CR率亦高于C组的CR率26．6％（P〈0．025），A组总有效率高于C组的总有效率63.3％，但差异不显著（P〉0．05）。结论初治惰性淋巴瘤病人采用FMD方案疗效优于复治病人；初治惰性淋巴瘤病人采用FMD方案疗效优于CHOP方案。Objective To compare the efficacy of fludarabin （ FLU ） combined with mitoxantrone （ MIT ） , dexamethasone （DXM） （FMD regime）, and CHOP persistent dripping regime in treatment of indolent lymphoma. Methods Seventy-three patients with first treatment and retreatment indolent lymphoma were divided into three groups. Group A was first treated with FMD; Group B was retreated with FMD; Group C was dripping continuously with CHOP. Results The total rate of CR in group A was 59.1%, and more than group B which was 28.6% （P〈0.05）. The total efficacy rate in group A was 86.4%, and more than group B which was 57.1% （ P〈0.05 ） . The total rate of CR in group A was also more than group C which was 26.6% （P〈0.025）. The total efficacy rate in group A was more than group C which was 63.3 %, but the difference was not significant （P〉0.05）. Conclusions The efficacy of patients with indolent lymphoma who were first treated with FMD might be better than those who were retreated with FMD. The efficacy of FMD could be better than CHOP persistent dripping regime in first treated patients.

关 键 词：氟达拉滨 CHOP持续滴注 惰性淋巴瘤 

分 类 号：R73-3[医药卫生—肿瘤]